Stanford Study: Ibogaine Reduces PTSD Symptoms by 88% in Veterans

A groundbreaking study published in Nature Medicine by researchers at Stanford University has demonstrated an 88% reduction in PTSD symptoms among military veterans following ibogaine treatment.

Study Highlights

• 30 veterans participated in the controlled study over 12 months
• Single treatment session produced lasting results at 6-month follow-up
• Disability ratings decreased by an average of 60% among participants
• No serious adverse events reported under medical supervision

Methodology

The study used the Clinician-Administered PTSD Scale (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5) to measure outcomes. Veterans received ibogaine hydrochloride under continuous cardiac monitoring in a clinical setting.

Implications

This study represents the strongest clinical evidence to date for ibogaine's efficacy in treating PTSD. The results are particularly significant given that many participants had been classified as "treatment-resistant" after failing multiple rounds of conventional therapy.

Dr. Nolan Williams, the study's lead researcher, noted: "These results suggest ibogaine could fundamentally change how we approach treatment-resistant PTSD."